Objective. The purpose of this study was to explore the development of a pre-clinical nuclear imaging model as a tool for testing novel radiopharmaceutical agents for imaging and/or delivery systems to human tissues. Here we report for the first time the imaging of human synovial tissue transplanted into SCID mice using a radiolabelled anti-E-selectin antibody and NanoSPECT/CT technology. Methods. Human synovium was transplanted into SCID mice. Two to three weeks post-transplantation tissue vasculature was stimulated with TNF-by intra-graft injection 5 h prior to intravenous injection of 111 In-labelled anti-E-selectin or isotype control antibody. At 1, 4, 24 and 48 h animals were imaged and transplant activity quantified. Results. Activity was detectable in the grafts at all time points, with clear delineation of the transplants in the reconstructed images. A significant difference in graft radioactivity was observed at 4 and 24 h with a significantly higher uptake (P < 0.05) of 111 In-anti-E-selectin compared with isotype control antibody. Conclusions. This article highlights NanoSPECT/CT imaging in the SCID mouse chimeric model as a powerful tool for the pre-clinical development of radiopharmaceutical and delivery agents targeting human synovial tissue in vivo.
Introduction
The imaging of inflammatory arthritis has advanced rapidly in recent years, particularly with developments in MRI and ultrasound technology, bringing the potential of earlier and more precise diagnosis, and the improved monitoring of response to treatment [1, 2] . The place of conventional nuclear imaging techniques has become increasingly uncertain: the most widely used radiotracer, 99m Tc-methylene diphosphonate (MDP), relies on the surrogate markers of increased blood flow and bone turnover adjacent to the area of inflammation, and hence is limited by poor specificity and diagnostic value [3] . A number of other non-specific tracers have been assessed with some success, including human immunoglobulin (HIg), liposomes and dextran, although none of these has entered routine clinical application [4] [5] [6] . The advent of mAbs and other compounds targeted at molecules implicated in the pathogenesis of RA has brought with it the prospect of molecular imaging, with clear potential for the diagnosis and sub-classification of synovitis. Of the agents so far assessed in clinical trials, antibodies to E-selectin have shown particular promise. E-selectin (previously known as ELAM-1) is an adhesion molecule implicated in the pathogenesis of RA, the expression of which is up-regulated in the inflamed synovial endothelium [7, 8] . Radiolabelled anti-E-selectin mAb 1.2B6 was initially assessed in porcine models of inflammation [9, 10] Tc-labelled HIg [11] [12] [13] . The pre-clinical development of novel agents for nuclear imaging has been hampered by the lack of availability of highresolution imaging systems for small animals; furthermore, mAb to human proteins may not be cross-reactive with murine epitopes (as is the case with 1.2B6), thus limiting their application in experimental arthritis models. Rapid recent advances in SPECT, including the use of multi-pinhole collimators, allows highresolution imaging with resolution <1 mm, enabling mouse physiology to be imaged on a scale equivalent to that possible in humans. Using a NanoSPECT/CT small-animal imaging system, in which SPECT and CT fusion images are acquired, we have imaged the uptake of radiolabelled mAb in a chimeric transplantation model in which human synovial tissue is transplanted into SCID mice. Of relevance to the work presented in this report, we have previously shown that: (i) grafts remain viable and become vascularized by mouse subdermal vessels as early as 7 days post-implantation; (ii) the graft vasculature forms chimeric anastomoses (human/mouse) at the edge of the transplants, whereas the transplanted tissue itself maintains expression of human cell adhesion molecules (CAMs); (iii) the anastomoses are patent and functional allowing for the delivery of mAbs against human CAMs; (iv) human CAMs, including E-selectin, can be modulated by intra-graft injection of TNF- [14, 15] . Here we report our findings with the use 111 In-labelled anti-Eselectin antibody to image these transplants, with quantification of graft uptake validating this model as a powerful tool for testing novel radiopharmaceutical agents for imaging of (or as delivery systems to) human tissues.
Materials and methods

Reagents and antibodies
All chemicals were obtained from the Sigma Chemical Company (Gillingham, UK) unless otherwise stated. mAb 1.2B6 is a mouse IgG 1 antibody that reacts with human and pig E-selectin, and which also reacts with lower affinity with human P-selectin. 1.2B6 hybridoma cells [16] were cultured in a CellLine 1000 Bioreactor (CellLine, Integra Biosciences, Switzerland) according to the manufacturer's instructions with cell culture media (RPMI þ 10% fetal calf serum, 5 ml penicillin and streptomycin (10 000 U Penicillin V and 5 mg streptomycin/ml), 4.5 g/l L-glutamine). Antibodies were purified by ultrafiltration and protein-G affinity chromatography. Purity was assessed using size-exclusion high performance liquid chromatography (SE-HPLC) and antibody concentration was determined by spectrophotometric absorbance at 280 nm.
Murine IgG 1 anti-human carcinoembryonic antigen (CEA) for use as an isotype control was obtained from the Biotherapeutics Development Laboratory at Cancer Research, UK.
Synovial tissue
Human synovial tissue was obtained from patients with OA undergoing joint replacement. Informed consent was obtained prior to the use of the tissues: ethical approval was obtained from the local ethics committee. Beige SCID CB-17 mice were maintained in a sterile environment: synovium was transplanted subcutaneously in a dorsal position distal to the shoulder joints (two transplants per animal) as previously described [15] .
Immunohistochemistry
OCT-embedded tissue was cut into 5 m sections in a cryostat (Leica Microsystems, Milton Keynes, UK) and placed onto glass slides (Superfrost Plus, VWR, Poole, UK). Slides were dried overnight and frozen at À808C until required. For staining, the slides were fixed in acetone, blocked with serum-free protein block (Dako, Ely, UK) and incubated in primary antibody anti-E-selectin or control anti-CEA diluted to 10 g/ml in antibody diluent (Dako) for 1 h at room temperature (RT). After washing, the slides were incubated with Envision HRP-conjugated antimouse/rabbit polymer (Dako) followed by the HRP substrate DAB and finally stained with haematoxylin. The sections were dehydrated and cleared by incubation in ethanol and xylene and mounted with Depex mounting medium. Pictures were taken on a light microscope (Olympus, Watford, UK) with a 20Â objective.
Conjugation of anti-E-selectin and control antibodies to DTPA and confirmation of immunoreactivity by ELISA
In order to enable labelling with 111 In, the antibodies were conjugated to the bifunctional chelating agent diethylenetriaminepenta-acetic acid (DTPA) using the method described by Cooper et al. [17] . Briefly, 5 mg of antibody in 0.1 M HEPES buffer pH 8.5 was incubated at 48C overnight with a 50-fold excess of isocyanatobenzyl-DTPA (SCN-Bn-DTPA) (Macrocyclics, Dallas, TX, USA) (50 mg/ml in ethanol). The following day the reaction mixture was purified and transferred into 0.1M ammonium acetate buffer pH 6 by ultrafiltration. The solution was filtered through a sterile 0.2 m syringe filter and stored in aliquots at À208C.
To confirm immunoreactivity of the 1.2B6 antibody to E-selectin post-conjugation to DTPA, ELISA was performed as follows: a 96-well plate (Maxisorb, Nunc, Roskilde, Denmark) was coated overnight at 48C with recombinant human E-selectin (R and D Systems, Abingdon, UK). After washing with PBS containing 0.05% Tween-20 (Sigma) and blocking with 2% BSA (VWR, Poole, UK) in PBS the diluted purified antibody and control antibodies were added to the wells with a further 1 h incubation at RT. After washing, HRP-conjugated goat antimouse antibody (Dako) was added followed by 3,3 0 ,5,5 0 -tetramethylbenzidine dihydrochloride (TMB). The reaction was stopped by the addition of H 2 SO 4 and the absorbance at 450 nm read in an automated plate reader (Anthos Scientific Instruments, Salzburg, Austria).
Radiolabelling
DTPA-conjugated antibody was diluted from concentrated stock to the desired concentration in 0.1 M ammonium acetate buffer pH 6.0. Fifteen MBq of 111 InCl 3 in 0.05 M HCl (Mallinckrodt Medical, Gosport, Hamphire, UK) not exceeding 20% of the total reaction volume was added to 7.5 g diluted antibody, the final volume being $15 l. After incubation for 30 min at RT, free 111 In was chelated by the addition of 10% volume 50 mM EDTA in 0.1 M ammonium acetate pH 6.0. The reaction mixture was incubated for a further 5 min at RT after which the labelling efficiency was determined by SE-HPLC on a Biosep-SEP S2000 column (Phenomenex, Macclesfield, UK) with isocratic 0.1 M phosphate buffer pH 7 þ 2 mM EDTA at 0.5 ml/min using Beckman System Gold (Beckman Coulter, High Wycombe, UK) running proprietary 24 Karat software with an inline UV detector (Beckman 168) and GABI radioactivity monitor (Raytest, Straubenhart, Germany) and instant TLC (ITLC) on silica-gel ITLC strips (Pall Life Sciences, Ann Arbor, MI, USA) with 0.1 M ammonium acetate pH 6.0 þ 50 mM EDTA as mobile phase. Strips were imaged using a Cyclone storage phosphor system (Perkin Elmer, Beaconsfield, UK) and the proportion of 111 In at the origin (bound) and at the solvent front (unbound) determined using proprietary software.
If radiolabelling efficiency was <95%, the antibodies were purified using Zeba 0.5 ml spin columns (Pierce, Caramlington, UK) using 0.067 M PBS pH 7.4 (Cambrex, Slough, UK) as the exchange buffer according to the manufacturer's instructions. Antibodies were diluted in PBS prior to injection.
Scanning protocol
A NanoSPECT/CT small-animal imaging system was used (Bioscan, Washington, DC, USA); this system employs a gantry of four NaI detectors with muti-pinhole collimators and has a resolution of $0.5 mm. The system incorporates parallel helical CT scanning, and proprietary software is used to reconstruct three-dimensional (3D) CT-SPECT fusion images. The software enables quantification of radioactivity with defined 3D regions of interest within the animals.
In order to up-regulate E-selectin expression by vascular endothelial cells in the transplanted synovial tissue, 200 ng of recombinant human (rh) TNF-(R and D systems, Abingdon, UK) in 50 l 0.9% saline was injected into each graft. After 5 h, the mice were injected with 2-4 MBq (2-6.5 g) of 111 In-labelled anti-E-selectin or isotype control antibodies. The animals were imaged at 1, 4, 24 and 48 h post-injection of antibody.
Prior to scanning, mice were anaesthetized in an anaesthetic chamber with 4% halothane and after induction anaesthesia was maintained with 2% halothane. The mouse was transferred to a bed kept at 378C on a gantry for imaging: gas anaesthesia was maintained for the duration of the scan. After acquisition of a CT topogram, the region for scanning acquisition was defined (typically full body or the region of the transplants only). The full scanning protocol was commenced with CT scan followed by inline SPECT with a minimum acquisition of 30 000 counts per projection. At the end of the study, tissues and transplants were retrieved for weighing and measurement of radioactivity in a gamma counter (LKB Wallac Compugamma 1282, Perkin Elmer, Beaconsfield, UK). The absolute activity was corrected for the graft weight and injected dose, and the results expressed as the percentage of the injected activity per gram of the tissue.
Statistical analysis
All statistical analysis was performed using Prism 3.0 software (Graphpad, San Diego, CA, USA). Data were analysed using an unpaired two-tailed t-test: significance was set at P 4 0.05. Nonlinear regression analysis was used to derive the EC50 of antibody binding in the ELISA.
Results
DTPA-conjugated 1.2B6 antibody retains affinity for E-selectin
In order to confirm that immunoreactivity for E-selectin was retained, DTPA-conjugated and unconjugated 1.2B6 antibodies were compared for binding to recombinant human E-selectin by ELISA. The results of this experiment are shown in Fig. 1A . A clear dose-response curve is seen confirming the immunoreactivity of the 1.2B6 antibodies. Non-linear regression analysis allowed the EC50 of each antibody to be compared and these were not significantly different, thus confirming that DTPA conjugation has no effect on immunoaffinity of 1.2B6 mAb for E-selectin. No significant immunoreactivity is seen with an isotype control antibody.
In order to confirm immunoreactivity on inflamed synovial tissue, frozen RA tissue sections were stained with equal concentrations of anti-E-selectin (1.2B6) or isotype-matched anti-CEA control antibodies. E-selectin expression by vascular endothelial cells is up-regulated in the synovium of patients with RA and RA tissue was therefore used to examine binding of anti-E-selectin antibodies to activated synovial endothelial cells. Representative sections are shown in Fig. 1B . As expected, specific staining of RA vessels is seen for E-selectin, with expression restricted to the vascular endothelium. No staining could be seen with the anti-CEA antibodies either on endothelial cells or elsewhere in the synovial tissue section thus confirming its suitability as a negative control.
Visualization of synovial tissue grafts by SPECT scan after intravenous administration of 111 In-antibodies
Antibodies were radiolabelled with 111 In to a specific activity of 0.5-1.4 MBq/g. Typically, radiolabelling yield as determined by ITLC was >95%: where radiolabelling efficiency was <95%, the antibody was purified from free 111 In by spin-column filtration, after which purity was >99%. Representative SE-HPLC chromatograms are shown in Fig. 2 . The large single peak seen with 280 nm absorbance confirms purity of the antibody (Fig. 2A) . A single peak of radioactivity is also seen, confirming >99% conjugation of 111 In to the antibody (Fig. 2B ). The aim of the imaging experiments was to determine whether the the NanoSPECT/CT imaging system could be used to visualize uptake of a systemically administered radiolabelled compound and, furthermore, to discriminate specific from non-specific uptake.
Two to three weeks after transplantation, the synovial grafts were injected with rhTNF-to stimulate expression of E-selectin by human endothelial cells. Five hours later the mice were injected intravenously with 2-4 MBq 111 In-labelled 1.2B6 (2-5 g) or isotype control mAb (3.5-6.5 g), with slightly higher quantity of control antibody due to lower specific activity. After 1 h and at 4, 24 and 48 h, mice were anaesthetized and imaged by the NanoSPECT/CT imaging system. Fusion images of the CT and SPECT scans clearly identified the transplanted tissues, thus enabling quantification, at all time points for both the 1.2B6 and control 111 In-labelled mAb. Representative SPECT/CT fusion images of 111 In-1.2B6-injected animals are shown in Fig. 3 . The 3D reconstruction (Fig. 3A) shows uptake of the 111 In-labelled 1.2B6 clearly visible in the transplants at 24 h. Sagital and transverse sections at the level of the transplants taken at 1 and 24 h show a clear increase in uptake of the radiolabelled antibody between the two time points. This indicates that the SCID mouse transplantation model is suitable for the dynamic imaging of antibody localization in vivo to transplanted synovium.
Significantly greater uptake of anti-E-selectin antibody vs anti-CEA is seen 24 h post-injection
The NanoSPECT/CT system allows, following image reconstruction, for the quantification of activity in defined regions. This has In (B, radioactivity in counts per minute). The large single peak confirms the purity of the protein (A) with >99% of 111 In conjugated to the antibody after purification (B).
the substantial advantage of enabling assessment of uptake in a transplant at multiple time points in the same animal. The accuracy of in vivo quantification by this novel small-animal SPECT/CT imaging system has not yet been extensively validated although some preliminary studies have been performed [18] . Thus, we assessed the quantification of graft uptake of an injected dose of radioactivity by comparing uptake as quantified from the SPECT scan with that of the ex vivo grafts as measured in a gamma counter.
For the quantification experiment, grafts were injected with TNF-5 h prior to the administration of 111 In-1.2B6 or control antibody in order to up-regulate E-selectin expression by the microvascular endothelium. NanoSPECT/CT images were acquired at 1, 4, 24 and 48 h: at the end of the experiment the transplanted tissues were retrieved and weighed, and the SPECTquantified activity plotted against that measured in the gamma counter. The results of the linear regression analysis are shown in Fig. 4 : highly significant correlation is seen between the radioactivity measured in the gamma counter and the measured radioactivity derived from the SPECT scans (with an r 2 ¼ 0.982). This was felt acceptable for the quantification of the graft uptake activity at multiple time points in single animals. Uptake of radioactivity in each of the two synovial grafts was measured at the indicated time points in each animal. CT/SPECT fusion images were produced using the proprietary software and a region of interest drawn around the transplants. The activity within the area was corrected for the weight of the grafts, which were retrieved after the animals were killed at 48 h, and for the injected dose. Finally, the results were corrected for the decay factor for the time between injection of the radioisotope and acquisition of the images. The graft uptake data (shown as percentage of the injected dose per gram of tissue plotted against time) are shown in Fig. 5 and it can be seen that there are significant differences in graft uptake between the anti-E-selectin and isotype control antibodies at 4 and 24 h (P < 0.05). The difference did not quite reach significance at 1 h (P ¼ 0.054) and there was a non-significant trend in favour of E-selectin at 48 h (P ¼ 0.14): this is likely to be related to the kinetics of expression of this molecule. To summarize, these experiments validate this model and technology for the testing of 'discovery' reagents as imaging or delivery systems to human tissues.
Discussion
The results presented in this report demonstrate that the SCID mouse transplantation model is a powerful and unique tool for the pre-clinical imaging of human synovium. The application of animal models to the development of novel imaging agents is hampered by the limited resolution of conventional 2D nuclear imaging techniques: consequently, it is often impossible to determine the sensitivity of novel agents prior to clinical trials. In activity derived from in vivo SPECT imaging was plotted against counts per minute measured of ex vivo transplants in a gamma counter. There is statistically significant correlation (r 2 ¼ 0.982) between the gamma counter and SPECT data: this confirms the suitability of imaging under these conditions for the quantification of graft uptake of radioactivity.
FIG. 5. Uptake of injected
111 In-labelled anti-E-selectin or control antibodies into transplants after intravenous injection. SPECT quantification of graft uptake of 111 In-labelled anti-E-selectin (1.2B6) and isotype control antibodies at 1, 4, 24 and 48 h. Human synovial tissue grafts transplanted into SCID mice were injected with TNF-5 h prior to intravenous administration of radiolabelled antibody. Mice were scanned at the indicated time points and the synovial graft activity quantified from the SPECT/CT images. Results are shown as percentage of the injected dose per gram of tissue (%id/g). Three mice per group, n ¼ 6 transplants (1.2B6), 5 transplants (control). Mean AE S.E.M.
However, advances in small-animal imaging techniques, particularly SPECT and PET scanning, both of which enable greater spatial resolution, are now enabling quantification of uptake within defined areas with some promising results [19, 20] . Whilst widespread use of PET is limited by the limited availability and short half-life of positron-emitting isotopes, SPECT uses isotopes already in widespread use such as 111 In and 99m Tc. Furthermore, multi-pinhole collimators further increase SPECT sensitivity with resolution greater than that of PET achievable in small-animal imaging systems [21] . A further disadvantage of animal models is that some labelled molecules intended for in vivo imaging may have restricted species specificity, such as that seen with the anti-E-selectin antibody used in this study which does not cross-react with the murine epitope.
We therefore investigated the use of a chimeric transplantation model, in which human synovial tissue is transplanted into SCID mice, as a platform model for the investigation of novel imaging agents. We have previously described this model and demonstrated that transplanted human synovial tissue has excellent survival at 2-4 weeks at which point macroscopic vascularization and microscopic anastomoses can be demonstrated [14] . We have also described this model in various applications, such as the demonstration of tissue homing of human leucocytes following adoptive transfer and the identification of novel synovial-specific homing peptide sequences by in vivo phage display [14] . Successful application of this model to the pre-clinical imaging of human synovial tissues would, for the first time, enable the development of novel imaging agents for inflammatory arthritis to be investigated without the initial need for human subjects: furthermore, dynamic imaging and quantification of tissue uptake at multiple time points could limit the numbers of animals required for such experiments.
Conventional bone scanning has become increasingly marginalized for the assessment of inflammatory arthritis as technologies in ultrasound and MRI have advanced. These techniques, which allow visualization of the inflamed synovial tissue itself rather than relying on the surrogate measures of local blood flow and permeability, have greater sensitivity in the diagnosis and monitoring of the disease [22] . Although a recent study has found that, in combination with MRI imaging, conventional scintigraphy can have some predictive value in the diagnosis of undifferentiated arthritis [23] , as a sole modality it has limited sensitivity to change and predictive value for the development of erosions. A number of agents which localize through (predominantly) non-specific means have been investigated (reviewed in [24] ): these exploit the known hyperpermeability of the highly neoangiogenic hyperplastic synovial tissue to macromolecules [25] . Examples of such agents are radiolabelled liposomes, dextran, nanocolloid and HIg each of which has had some success in human studies [4] [5] [6] 26] . HIg has shown particular promise in inflammatory arthritis [27] and has compared favourably with conventional bone scanning after radiation synovectomy and in inflammatory arthritis [6, 28] : despite this it has yet to come into routine clinical use. A second group of agents is taking advantage of specific molecular targeting techniques to image the disease process: despite impressive technical advances in this area [29] , the aforementioned synovial hyperpermeability and consequent component of non-significant localization of these agents impairs the detection of specific uptake. Examples of such agents that have been tried are 123 I-labelled IL-1 receptor antagonist (IL1-ra), which did not show increased localization compared with radiolabelled albumin [30] , and 99m Tc-labelled antibody to TNF- [31] . The latter tracer was taken up by inflamed joints and this was sensitive to steroid treatment, although pre-treatment with blocking antibodies suggested that the majority (75%) of this uptake was non-specific. E-selectin is an excellent candidate for targeted molecular imaging in RA: it is expressed by the inflamed microvascular endothelium and is implicated in the recruitment of inflammatory cells into the tissue [32] . E-selectin can be expressed at low levels in uninflamed tissue, including the synovium [33] , but is up-regulated in inflammatory synovitis [7, 34] and this is reduced following treatment such as TNF--blocking therapy [35] . A further important advantage of E-selectin targeting is the internalization of the ligand/receptor complex following ligation [36] . After initial success in a porcine arthritis model [37] 1.2B6 has shown considerable promise in studies of patients with RA showing favourable properties compared with conventional bone scans and radiolabelled HIg scintigraphy [11] [12] [13] .
We and others have previously shown that the inflammatory phenotype of transplanted synovial tissue is significantly downregulated at 2-4 weeks, and that intragraft injection of TNFresults in up-regulation of inflammatory molecules including E-selectin [15, 38] . TNF-would also be expected to enhance endothelial permeability within the grafts [39] and hence it was critical that specific vs non-specific uptake were assessed. An isotype control antibody was therefore used which was non-reactive with the target epitope or RA synovial tissue sections. The results of this experiment clearly demonstrate that whereas there is substantial non-specific uptake within the grafts, there is significantly greater uptake of the anti-E-selectin antibody. Thus, this technique has the sensitivity to discriminate enhanced uptake of a specific agent. The difference that we have shown between localization of the 1.2B6 antibody and non-specific mAb in this model adds further support to the potential for the development of E-selectin-targeted agents for the imaging of inflamed synovium. It should be noted that the 1.2B6 antibody also binds P-selectin with low affinity: P-selectin is also expressed in the vascular endothelium of RA synovial tissue [40] -the increased uptake seen may therefore also represent P-selectin binding to some degree, although this does not detract from our conclusions to this work.
The clinical use of 3D nuclear imaging techniques in inflammatory arthritis is still at a relatively early stage. A number of studies have investigated 18 FDG-PET imaging of the inflamed synovium with promising results [41] [42] [43] : there has also been a report of whole-body PET imaging in RA [44] -the imaging of multiple joints in a single scan is a significant potential advantage of PET imaging. There have been relatively few reports of the application of SPECT imaging to inflammatory arthritis, with resolution likely to be the major deterrent to those considering its use: however, recent advances in SPECT technology and the use of multi-pinhole collimators have made SPECT more attractive. A translational study of high-resolution SPECT imaging in a murine arthritis model and in patients with RA was encouraging and suggested that SPECT may be able to detect early evidence of arthritis with a sensitivity comparable with that of MRI [19] . This study used a conventional MDP-based tracer and it is therefore tempting to speculate how much greater sensitivity could be achieved with specific agents.
There are, of course, limitations to this model, particularly that the synovium is not being imaged in the context of the joint: resolution of synovial tissue uptake from other articular structures is not tested under these conditions. Furthermore, there are significant differences in the expression of inflammatory molecules in fresh and transplanted synovium: in this study TNF-was used to up-regulate E-selectin expression but expression of other target molecules in the transplants would need to be validated prior to experiments with other agents. Despite this it gives a unique platform to image changes over time in the same tissue with evident applications to the testing of novel radiopharmaceutical agents, and in particular their capacity to resolve specific from non-specific uptake and consequent potential to image specific molecules. We have also described the successful xenografting of other non-malignant human tissues such as lymph node and skin [14, 45] and the model could therefore have potential in a variety of non-rheumatological areas. Whilst clearly not a substitute for the imaging of human arthritis in situ,
